Enhanced anti-tumor immunity ensued blockade of the T cell checkpoint receptor programmed death (PD) receptor-1, which released ILC2 cell-intrinsic inhibition to expand and activate the tumor ILC2s to produce CCL5, thereby resulting in CD103+ dendritic cell expansion and then CD8 + T-cell activation (Moral et al., 2020). Here, CCL5 is linked to neoplasm.